Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Dear Manufacturer: Immune Globulin Intravenous (Human) (IGIV); Class Label Extension

Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448

December 1, 2003

Dear Manufacturer,

Please refer to the October 16, 2003 letter regarding your Immune Globulin Intravenous (Human) (IGIV) in which FDA required updates to your product labeling.

This letter is notification that FDA is extending the deadline for the submission of the CBE required in that letter by an additional 45 days. The due date to submit this supplement to your Biologics License is January 14, 2004.

Please indicate in the cover letter of the supplement the date by which you expect to implement the changes.

If you have any questions concerning this letter, please contact Michael Wiack of the Division of Blood Applications, at 301-827-3524.

Sincerely yours,

--- signature ---

Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Contact FDA

(800) 835-4709
(240) 402-8010
Manufacturers Assistance and Technical Training Branch (CBER)

Division of Manufacturers Assistance and Training

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 02/11/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.